1) Response to CART #meso associated with density of infiltrative TILs with PDL1 and TIGIT as potential targets of resistance. Explains what we see with better outcomes for CART-meso followed by anti-PD1? aacrjournals.org/cancerres/arti…2) Data on TEAD inhibitors in #meso. No MTD reached. Response does not correlate with NF2 mutation status. Will need to confirm with larger n. @IbiayiMD@curemeso